Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Issued (2017 - 2023)

Aclaris Therapeutics has reported Shares Issued over the past 7 years, most recently at $26.7 million for Q3 2023.

  • Quarterly results put Shares Issued at $26.7 million for Q3 2023, up 136.74% from a year ago — trailing twelve months through Dec 2024 was $26.7 million (up 158.21% YoY), and the annual figure for FY2024 was $32000.0, down 99.88%.
  • Shares Issued for Q3 2023 was $26.7 million at Aclaris Therapeutics, up from $37000.0 in the prior quarter.
  • Over the last five years, Shares Issued for ACRS hit a ceiling of $72.7 million in Q2 2022 and a floor of -$72.6 million in Q3 2022.
  • Median Shares Issued over the past 5 years was $102000.0 (2019), compared with a mean of $2.9 million.
  • Peak annual rise in Shares Issued hit 6870.95% in 2022, while the deepest fall reached 91.11% in 2022.
  • Aclaris Therapeutics' Shares Issued stood at $122000.0 in 2019, then tumbled by 79.51% to $25000.0 in 2020, then surged by 4072.0% to $1.0 million in 2021, then crashed by 96.45% to $37000.0 in 2022, then soared by 72018.92% to $26.7 million in 2023.
  • The last three reported values for Shares Issued were $26.7 million (Q3 2023), $37000.0 (Q4 2022), and -$72.6 million (Q3 2022) per Business Quant data.